| Literature DB >> 35982863 |
Azadehalsadat Hosseini Dastgerdi1, Mahtab Ghanbari Rad1, Nepton Soltani1.
Abstract
Insulin resistance (IR) is a chronic pathological condition that is related to reduce the rates of glucose uptake, especially in the liver, muscle, and adipose tissue as target tissues. Metabolic syndrome and type 2 diabetes mellitus can occur following progression of the disease. The majority of prior research has applied that some cations such as magnesium (Mg2+) have important physiological role in insulin metabolism. Mg2+ is the fourth most abundant mineral in the human body that gets involved as a cofactor of various enzymes in several metabolic events, such as carbohydrate oxidation, and it has a fundamental role in glucose transporting mechanism of the cell membrane. This cation has numerous duties in the human body such as regulation of insulin secretion in pancreatic beta-cells and phosphorylation of the insulin receptors in target cells and also gets involved in other downstream signal kinases as intracellular cation. On this basis, intracellular Mg2+ balancing is vital for adequate carbohydrate metabolism. This paper summarizes the present knowledge about the therapeutic effects of Mg2+ in reducing IR in liver, muscle, and pancreases with different mechanisms. For this, the search was performed in Google Scholar, PubMed, Scopus, and Web of Science by insulin resistance, skeletal muscle, liver, pancreases, magnesium, Mg2+, and inflammation keywords. Copyright:Entities:
Keywords: Diabetes; glucose; insulin resistance; magnesium
Year: 2022 PMID: 35982863 PMCID: PMC9379913 DOI: 10.4103/abr.abr_366_21
Source DB: PubMed Journal: Adv Biomed Res ISSN: 2277-9175
Studies that have examined the role of magnesium in improving insulin resistance
| Protective effects of Mg2+ | ||||
|---|---|---|---|---|
|
| ||||
| Source | Doses | Time of administration | Effect | References |
| MgSO4 | 1 or 2 mg/kg diet | 4 weeks | Mg2+ supplementation improved glucose tolerance, lowered BG levels, lipid perturbations and HOMA-IR index. Mg2+, on the other hand, was able to increase insulin sensitivity and INR and GLUT4 | [ |
| MgSO4 | 10 g/l drinking water | 12 weeks | MgSO4 lowered BG, glucose tolerance and HbA1c relative to the diabetic group. Also Mg2+ increased GIR in diabetics | [ |
| Elemental high-potency, highly absorbable magnesium (oxide, gluconate, lactate) | 250 mg/d tablet | 3 months | Administration of Mg2+ indicated a significant improvement in HbA1C, insulin levels, C-peptide, HOMA-IR and HOMA-β% | [ |
| MgCl | 300 mg/day (50 gr of MgCl2 by 1000 ml of solution) | 12 weeks | Mg2+-supplemented subjects significantly increased their serum Mg2+ levels and reduced HOMA-IR index | [ |
| Mg2+ supplementation | 360 mg/day | 4–16 weeks | Oral Mg2+ supplementation was effective in reducing plasma fasting glucose levels and raising HDL cholesterol in patients with T2D diabetes | [ |
| Mg–aspartate–hydrochloride | 365 mg/day | 6 months | Mg2+ supplementation resulted in a significant improvement of fasting plasma glucose and some insulin sensitivity indices. Mg2+ prevent IR and subsequently T2D diabetes | [ |
| MgSO4 | 300 mg/d | 3 months | Administration of Mg2+ significantly improved fasting BG, 2 h postprandial glucose, lipid profile, and hepatic enzymes | [ |
| Magnesium oxide | 250 mg/day | 6 weeks | Mg2+ significantly improved glycemic control and lipid profiles | [ |
| MgSO4 | 10 g/l of | 16 weeks | Administration of MgSO4 improved IPGTT, lowered BG levels, and decreased FoxO1 and PEPCK genes and proteins expression in muscle and liver | [ |
IR: Insulin resistance, HOMA-IR: Homeostatic model assessment for IR, BG: Blood glucose, INR: Insulin receptor, HbA1c: Hemoglobin A1c, GLUT: Glucose transporter, T2D: Type 2 diabetes mellitus, HDL: High-density lipoprotein, Mg2+: Magnesium, MgSO4: Magnesium sulfate IPGTT: Intraperitoneal glucose tolerance test: for measures the clearance of an intraperitoneally injected glucose load from the body. It is used to detect disturbances in glucose metabolism that can be linked to condition such as diabetes or metabolic syndrome., GIR: Glucose infusion rate: shows the rate at which glucose enters the cell and is inversely related to IR
Figure 1Role of magnesium in reducing insulin resistance in the pancreas, muscle, and liver. GLUT1: Glucose transporter 1, GLUT4: Glucose transporter 4, IRS1: Insulin receptor substrate 1, Mg: Magnesium, PPAR: Peroxisome proliferator-activated receptors, FOXO1: Forkhead box protein O1, FEPCK: Phosphoenolpyruvate carboxykinase, G6Pase: Glucose 6-phosphatase, MAPK: Mitogen-activated protein kinase, PFK-1: Phosphofructokinase-1, GK: Glucokinase
Figure 2Role of magnesium in reducing inflammation and oxidative stress. INR: Insulin receptor, NFKB: Nuclear factor-kappa B, JNK: c-Jun N-terminal kinases, TNFα: Tumor necrosis factor-alpha, IL1: Interleukin-1, IL6: Interleukin-6, PI3K: Phosphoinositide 3-kinases, GLUT4: Glucose transporter 4, AKT (PKB): Protein kinase B, ROS: Reactive oxygen species, Mg: Magnesium